Jacobs Levy Equity Management
VKTX icon

Jacobs Levy Equity Management’s Viking Therapeutics VKTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-487,313
Closed -$1.32M – 1047
2022
Q3 		$1.32M Buy
+487,313
New +$1.6M 0.01% 647

Other funds holding VKTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management's VKTX Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of Viking Therapeutics (VKTX) in Q4 2022, closing a stake of 487,313 shares — an estimated $1.32M sold.

Jacobs Levy Equity Management first reported a position in VKTX in Q3 2022 and held it in 1 quarter. The position peaked at $1.32M in Q3 2022. 129 funds tracked by Wall St. Rank hold VKTX as of Q4 2022.

  • Jacobs Levy Equity Management reported no remaining Viking Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 487,313 Viking Therapeutics shares in Q4 2022, an estimated $1.32M.
  • Jacobs Levy Equity Management first reported a position in Viking Therapeutics in Q3 2022 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Viking Therapeutics position peaked at $1.32M in Q3 2022.
  • 129 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.